ANZUP Chair Welcome
ANZUP Convenors Welcome
ANZUP Trainee Day Convenors Welcome
ANZUP Committees
Agenda for Third Annual General Meeting
Sponsors Acknowledgements
International Speakers
National Speakers
Scientific Program and Pre-Conference Meetings
PREDICTIVE/PROGNOSTIC MARKERS IN RENAL CELL CANCER: “INSIGHTS FROM THE DATABASE CONSORTIUM” : 001
CONTEMPORARY CONCEPTS AND CONTROVERSIES IN THE DIAGNOSIS AND MANAGEMENT OF UPPER TRACT UROTHELIAL CARCINOMA (UTUC) : 002
OPTIMAL MANAGEMENT OF BLADDER CANCER - INTEGRATING SURGERY AND SYSTEMIC THERAPY : 003
CONTROVERSIES IN POST-PROSTATECTOMY RADIOTHERAPY AND ANDROGEN SUPPRESSION IN PROSTATE CANCER : 004
SURVEILLANCE FOR STAGE I TESTICULAR CANCER : 005
DECISION SUPPORT FOR PROSTATE CANCER TREATMENT : 006
RAVES/TROG STUDIES UPDATE : 007
MINDFULNESS INTERVENTION STUDY UPDATE : 008
PROCARE/PC4 STUDY UPDATE : 009
PRIAS STUDY UPDATE : 010
EVERSUN STUDY UPDATE : 011
SORCE STUDY UPDATE : 012
CURRENT CLINICAL TRIALS IN RENAL CELL CANCER IN CANADA : 013
RAD001 AND ZOLEDRONIC ACID IN RENAL CELL CARCINOMA PATIENTS WITH BONE METASTASES (RAZOR) - A RANDOMIZED PHASE II TRIAL : 014
NSW CANCER CLINICAL TRIALS NETWORK : 015
SEXUAL REHABILITATION FOR ERECTILE DYSFUNCTION : 016
SAFE USE OF TYROSINE KINASE INHIBITORS FOR RENAL CELL CANCER IN ORGAN FAILURE : 017
WILL THE ILL EFFECTS OF TREATMENT ON THE EXPERIMENTAL ARMS OF THE RADAR TRIAL FOR MEN WITH LOCALLY ADVANCED PROSTATE CANCER BE WORTH IT? : 018
QOL FOR INTERMITTENT ANDROGEN DEPRIVATION THERAPY : 019
ANDROGEN SUPPRESSION IN PROSTATE CANCER - WHO, WHEN, AND HOW LONG : 020
CONTEMPORARY PATTERNS OF DISEASE, PATIENT, AND MANAGEMENT CHARACTERISTICS FROM A POPULATION-BASED RAPID-ACCESS CLINICAL POPULATION-BASED REGISTRY IN VICTORIA : 021
IMPACT OF RENAL IMPAIRMENT AND GRANULOCYTE COLONY STIMULATING FACTOR (GCSF) ON BLEOMYCIN INDUCED PNEUMONITIS (BLEO LUNG), FEBRILE NEUTROPENIA (FN) AND SURVIVAL IN CHEMOTHERAPY (CHEMO) TREATED GERM CELL TUMOR (GCT) PATIENTS (PTS) : 022
PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MODAFINIL FOR FATIGUE IN PATIENTS TREATED WITH DOCETAXEL-BASED CHEMOTHERAPY : 023
PERI-OPERATIVE CHEMOTHERAPY IMPROVES RELAPSE-FREE SURVIVAL FOR UROTHELIAL CARCINOMA OF THE BLADDER TREATED BY RADICAL CYSTECTOMY, BUT REMAINS UNDERUTILISED IN AN AUSTRALIAN TERTIARY REFERRAL INSTITUTION : 024
ACCELERATED BEP STUDY UPDATE : 025
CHEMOTHERAPY-COGNITION STUDY UPDATE : 026
STAGE II SEMINOMA : 027
GENE EXPRESSION STUDIES OF PLATINUM RESISTANCE IN TESTICULAR GERM CELL TUMOURS : 028
CIRCULATING TUMOUR CELLS : 029
TISSUE BIOMARKERS : 030
DEVELOPMENTAL THERAPEUTICS : 031
GENETIC EPIDEMIOLOGY : 032
EORTC QUALITY OF LIFE MODULE DEVELOPMENT ILLUSTRATED WITH NEW QLQ-TC26 FOR TESTICULAR CANCER : 033
ADAPTIVE RADIOTHERAPY TECHNIQUES : 034
INNOVATIONS IN INTRA-VESICAL CHEMOTHERAPY : 035
SURGICAL OUTCOME IN BLADDER CANCER : 036
NEW SYSTEMIC TREATMENT FOR PROSTATE CANCER - NOVEL ANTI-ANDROGENS, BONE AGENTS AND CHEMOTHERAPY : 037
ROLE OF MRI FOR ACTIVE SURVEILLANCE IN PROSTATE CANCER : 038
CYTOGENETIC CHANGES IN RENAL CELL CARCINOMA: BASIS FOR SENSITIVITY AND RESISTANCE TO EVEROLIMUS : 101
IMPROVING EVIDENCE BASED CARE FOR LOCALLY ADVANCED PROSTATE CANCER: A RANDOMISED PHASED TRIAL OF CLINICAL GUIDELINE IMPLEMENTATION THROUGH A CLINICAL NETWORK : 102
LYMPHADENECTOMY WITH RADICAL CYSTECTOMY AT AN AUSTRALIAN TERTIARY REFERRAL INSTITUTION: TIME TRENDS AND IMPACT ON ONCOLOGICAL OUTCOMES : 103
LOWER LEVELS OF SERUM TESTOSTERONE, QUALITY OF LIFE, AND TREATMENT FOR TESTICULAR CANCER: A PROSPECTIVE COHORT STUDY : 104
THE GREEN WHISTLE: A NOVEL METHOD OF ANALGESIA FOR TRANSRECTAL PROSTATE BIOPSY : 105
EFFICACY OF SORAFENIB IN ADVANCED RENAL CELL CARCINOMA INDEPENDENT OF PROGNOSTIC GROUP AND HISTOLOGY SUBTYPES : 106
COUPLE DISTRESS FOLLOWING PROSTATE CANCER DIAGNOSIS : 107
/ STREET-VIEW.COM /: REFERRAL PATTERNS AND PATIENT EVALUATION OF CLINICAL PSYCHOLOGY SERVICES IN A UROLOGY DEPARTMENT : 108
SUN EXPOSURE IS ASSOCIATED WITH INCREASED INCIDENCE AND POORER SURVIVAL OF PROSTATE CANCER IN THE HIGH UV ENVIRONMENT OF AUSTRALIA : 109
BLADDER CARCINOMA IN SITU IN AUSTRALIA: A RISING INCIDENCE FOR AN UNDER-REPORTED MALIGNANCY : 110
A RETROSPECTIVE ANALYSIS OF 100 MEN WITH PROSTATE CANCER: DOES HIF1 DETERMINE CASTRATE RESISTANCE AND ITS CHARACTERISTICS? : 111
PHASE I STUDY OF A POLY(ADP)-RIBOSE POLYMERASE (PARP) INHIBITOR MK-4827 (MK) WITH ANTITUMOUR ACTIVITY IN SPORADIC CASTRATION RESISTANT PROSTATE CANCER (CRPC) : 112
IMPACT OF TYPE OF NERVE SPARING DURING ROBOT ASSISTED RADICAL PROSTATECTOMY PROCEDURE ON MARGIN STATUS AND POST-OPERATIVE POTENCY : 113
A SYSTEMATIC REVIEW OF STEREOTACTIC ABLATIVE BODY RADIOTHERAPY FOR PRIMARY RENAL CELL CARCINOMA : 114
A NOVEL DIAGNOSTIC TOOL FOR DETECTING PROSTATE CANCER : 115
AUSTRALIAN PROSTATE CANCER BIORESOURCE, 2012 : 116
Company Profiles